An inflammatory cytokine signature predicts COVID-19 severity and survival
2020 · Nature Medicine · 2,683 citations
https://doi.org/10.1038/s41591-020-1051-9
C
Carlos Cordon‐Cardo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
935
Papers
97.5K
Citations
154
h-index
539
i10-index
Carlos Cordon‐Cardo is an academic researcher from Mount Sinai Hospital. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Cancer-related Molecular Pathways & Prostate Cancer Treatment and Research. The author has an h-index of 154, co-authored 795 publications.
ORCID: 0000-0003-0858-5624Papers by this author
works17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
2002 · PubMed · 435 citations
Validation of Tissue Microarrays for Immunohistochemical Profiling of Cancer Specimens Using the Example of Human Fibroblastic Tumors
2001 · American Journal Of Pathology · 408 citations
https://doi.org/10.1016/s0002-9440(10)64075-8
Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
2015 · Nature Communications · 284 citations
https://doi.org/10.1038/ncomms7087
Targeting cancer stem cells to suppress acquired chemotherapy resistance
2013 · Oncogene · 241 citations
https://doi.org/10.1038/onc.2013.411
Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth
1998 · Nature · 195 citations
https://doi.org/10.1038/31008
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat